Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations

Table 3

Ongoing clinical trials in DSRCT.

Clinical trial (ID); phase	Drugs	Current status	Assigned intervention
NCT01189643; pilot study	CPT-11, TMZ, bevacizumab	Ongoing but not recruiting	Two cycles of the investigational combination irinotecan, temozolomide, and bevacizumab will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery
NCT01099644; phase I	Biological: ^131I-8H9	Recruiting	Intraperitoneal Radioimmunotherapy With ^131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
NCT02173093; phase I	Biological: IL-2 | biological: GD2Bi-aATC | biological: GM-CSF	Recruiting	Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma, DSRCT
NCT02982941; phase I	Drug: enoblituzumab	Recruiting	Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
NCT01532687; phase II	Gemcitabine ± pazopanib	Recruiting	Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
NCT00089245; phase I	Radiation: iodine I-131 monoclonal antibody 8H9	Recruiting	Radiolabeled Monoclonal Antibody Therapy in Treating Patients with Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer/Sarcomas